Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom's (DXCM) quarterly Notes Payables came in at $1.2 billion in Q3 2025, little changed on a QoQ basis from $1.2 billion in Q2 2025.

Dexcom (DXCM) Notes Payables (2022 - 2025) Analysis & Trends

Dexcom (DXCM) has 4 years of Notes Payables data on file, last reported at $1.2 billion in Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $1.2 billion in Q3 2025; TTM through Sep 2025 was $1.2 billion, a N/A change from a year earlier, with the FY2024 full-year figure at $1.2 billion, changed N/A from the prior year.
  • Notes Payables for Q3 2025 stood at $1.2 billion, roughly flat from $1.2 billion in the prior quarter.
  • Over the last five years, Notes Payables for DXCM reached as high as $1.2 billion in Q3 2025 and fell as low as $124.2 million in Q3 2023.
  • Historically, Notes Payables has averaged $908.3 million across 4 years, with a median of $989.1 million in 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 Steris 21.47 Bn 21.03 Bn 697.10 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 1.21 Bn
Jun 30, 2025 1.21 Bn
Mar 31, 2025 1.21 Bn
Dec 31, 2024 1.20 Bn
Sep 30, 2023 124.20 Mn
Jun 30, 2023 773.80 Mn
Mar 31, 2023 773.20 Mn
Dec 31, 2022 772.60 Mn